Full-Time

Associate Director

Growth

Ro

Ro

1,001-5,000 employees

Online telemedicine platform with prescription delivery

Compensation Overview

$168.3k - $200k/yr

+ Equity

New York, NY, USA

Hybrid

Tri-state NY area: HQ on Tue/Thu; outside tri-state: in-person collaborations throughout the year.

Category
Growth & Marketing (1)
Required Skills
Mixpanel
Requirements
  • 8 - 10 years of proven experience driving performance marketing at scale, including ownership of budgets within paid marketing programs with 8-to-9 figure annual spend budgets, and 8-figure paid social budgets specifically
  • Deep “hands on keyboard” experience and spend ownership responsibility as channel manager in previous roles, with strong expertise in paid social
  • Strong creative judgment and a track record of deftly balancing brand and performance considerations to scale creative output without sacrificing quality
  • Ability to operate as a cross-channel integrator: comfortable going deep in platforms and data (even if you’re not the day-to-day channel owner) and partnering effectively with specialists
  • Clear communicator (both written and verbal) with and ability to work effectively across junior and senior stakeholders alike
  • High analytical fluency and comfort in self-serve diagnosis (Mixpanel and paid platform data); ability to translate insights into clear action plans
  • Strong experimentation and funnel/CRO mindset with a deep understanding of how landing pages, funnels, and lifecycle work together with paid media
  • Familiarity with incrementality and measurement approaches (use of frameworks/tools like Haus a plus)
  • Demonstrated ability to use AI to create leverage in creative development workflows, insight generation, iteration speed, or operational throughput
  • Mission alignment: genuine excitement to work on categories like Sexual Health and Dermatology and to serve the needs of those patients through our growth efforts
Responsibilities
  • Own portfolio performance outcomes across SDF, driving growth within CPA guardrails and LTV-based benchmarks
  • Quarterback the full paid channel mix (paid social, search, YouTube/online video, affiliate, partner/endorser investments, offline), partnering with channel managers to set goals and priorities, unblock execution, and improve results
  • Fuel creative-led growth by optimizing a creative testing engine that produces hundreds of net-new assets per month across in-house, UGC, agency, and external resources, and working closely with internal teams to drive high output at high quality
  • Establish and refine quarterly roadmaps for channel focus, testing priorities, and where the team should invest time, dollars, and effort—then iterate based on learnings and performance data
  • Monitor performance daily across KPIs using tools like Mixpanel, Hex, and channel platforms; identify drivers, proactively flag anomalies, and recommend corrective actions quickly
  • Serve as the owner of paid conversion metrics and constantly identify, size and advocate for new opportunities to drive CVR gains across the full funnel, from ad to checkout
  • Guide our CRM efforts across the lifecycle journey, from acquisition through to retention and with an eye on how CRM campaigns mesh tightly with our paid channel strategy
  • Own and refine the operating model for how we establish and pursue business goals. Rally the core team and stakeholders against priorities and key decisions to move with clarity and speed
  • Drive improvement in our performance asset creation process, including Airtable/workflow prioritization, review SLAs, and bottleneck removal to maintain high creative throughput
  • Become an expert in our marketing and data stack and collaborate closely with the Growth Analytics team to develop improved performance measurement – through both the buildout of new tools as well as the application of incrementality principles to run tests and experiments
  • Partner with FP&A on payback analysis, pricing strategy, financial forecasting and monthly reconciliation (credits, billing issues, accrual accuracy)
Desired Qualifications
  • Familiarity with advanced AI-powered creative development workflows or AI-assisted optimization techniques beyond basic AI usage
  • Experience with Haus incrementality measurement framework or similar
  • Previous leadership experience in growth or marketing leadership roles

Ro.co provides online telemedicine services for adults to manage health from home. Patients complete an online visit; US-licensed clinicians review symptoms and medical history to diagnose and recommend personalized treatment, which may include a prescription shipped directly to the patient with free shipping. The service emphasizes privacy and security, adhering to applicable laws and implementing protective measures for data. Its goal is to deliver convenient, end-to-end online care—from consultation to prescription—without in-person visits.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$1B

Headquarters

New York City, New York

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 market expansion drives recurring revenue through Body membership and ongoing side effect management.
  • Cross-selling potential: 20% of patients adopt second health vertical within 30 days of signup.
  • Ro.OS platform scales provider capacity and improves care quality across millions of patients nationwide.

What critics are saying

  • GLP-1 supply shortages force patients to competitors offering compounded alternatives at lower prices.
  • DEA enforcement of Ryan Haight Act eliminates telehealth prescribing for controlled substances like Adderall.
  • Class-action litigation over GLP-1 side effects like gastroparesis exposes Ro to multimillion-dollar settlements.

What makes Ro unique

  • Vertically integrated platform seamlessly connects telehealth, diagnostics, pharmacy, and ongoing care monitoring.
  • Real-time side effect tracking and 24/7 messaging enable rapid patient support versus traditional care.
  • Direct partnerships with Novo Nordisk and Eli Lilly provide exclusive pricing and first-day drug launches.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Ro who can refer or advise you

Benefits

Medical, dental, & vision benefits

One Medical membership

Equity

Flexible Time Off

Gym reimbursement stipend

Learning & development stipend

Paid parental leave

Flexible work arrangements

Dog-friendly office

Company-wide events

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Ro
Mar 31st, 2026
Ro Helps Patients save up to $1,200 per year on Wegovy(R) through collaboration with Novo Nordisk.

Ro Helps Patients save up to $1,200 per year on Wegovy(R) through collaboration with Novo Nordisk. The Wegovy(R) injectable and pill are now available at even lower cash pay prices on Ro March 31, 2026 - Ro, the leading direct-to-patient healthcare company, today announced that patients can save up to $1,200/year on the Wegovy(R) pen or $600/year on the Wegovy(R) pill through its collaboration with Novo Nordisk. The new savings options (including 3, 6, and 12 month prepaid plans) enable cash paying patients to access new, lower prices available for both the Wegovy(R) pen or pill. In addition, patients will soon be able to save with new, lower price Ro Body membership options. "At Ro, we fight every day to help patients achieve their health goals - but goals don't matter if treatment isn't within reach. Affordability is access, and helping patients save up to $1,200 per year on Wegovy(R) is a meaningful step toward breaking down that barrier for millions more people," said Zach Reitano, CEO and co-founder of Ro. "Working with Novo Nordisk, we're pushing forward a new model for how life-changing GLP-1 treatments reach patients - more affordably and at scale." Since April of 2025, Ro has worked with Novo Nordisk to help more patients access FDA-approved GLP-1 medications at the best available cash prices. Most recently, Ro launched Novo's new Wegovy(R) pill on its direct-to-patient platform - making the pill an option to patients nationwide on day one of its market availability. This first-of-its-kind drug launch helped meet the incredible demand for the only FDA-approved oral GLP-1 weight loss medication and make it one of the most successful launches ever. "More and more people are turning to direct-to-patient channels like Ro that seamlessly offer FDA-approved medicines and weight loss support with a convenient, end-to-end experience. By introducing new subscription pricing for Wegovy(R) at our lowest prices, we're giving people even more control over their care journey, with transparent payment options that fit their individual needs," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. In April, Ro will also introduce new options offering significant savings for the Body membership, enabling patients access to high-quality ongoing care, 24/7 messaging, progress tracking and side effect monitoring, and 1-1 coaching. For those who want to check their insurance coverage, Ro's GLP-1 Insurance Checker has helped over 2 million people understand their benefits, so they can get their medication at the lowest possible price - whether that's using insurance coverage or paying cash. See Important Safety Information about GLP-1 medications, including Boxed Warning, at ro.co/safety. About ro. Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients in nearly every single county in the United States, including 99% of primary care deserts. Visit Ro.co for more information. See more news from ro. Ro Debuts First-Ever Super Bowl Commercial Starring Serena Williams to Launch "Healthier on Ro" Campaign Ro Announces Research Collaboration to Better Understand and Improve the Real-World Patient Experience with GLP-1s Ro Launches Wegovy(R) Pill Through Integration with Novo Nordisk New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials Ro to Present Eight Research Abstracts at ObesityWeek 2025 Ro Collaborates with Leading Obesity Researchers to Debut New, Validated Scale to Measure 'Food Noise' Serena Williams joins Ro as GLP-1 Celebrity Ambassador Ro introduces one-month $199 Wegovy(R) new patient offer and discounted Body membership Charles Barkley partners with Ro as GLP-1 celebrity ambassador Ro integrates with NovoCare(R) Pharmacy to provide seamless access to Wegovy(R) at the lowest cash price Ro works with Lilly to streamline patient access to authentic Zepbound(R) single-dose vials by integrating with Lilly's pharmacy channel

Femtech Insider
Aug 22nd, 2025
Serena Williams Partners with Ro as GLP-1 Weight Loss Ambassador

Tennis champion Serena Williams has joined direct-to-patient healthcare company Ro as a celebrity patient ambassador for GLP-1 weight loss medications.

PR Newswire
May 22nd, 2025
Ro Introduces One-Month $199 Wegovy New Patient Offer And Discounted Body Membership

Patients can come to Ro for the lowest cost FDA-approved GLP-1s anywhereNEW YORK, May 22, 2025 /PRNewswire/ -- Ro today announced it is offering Novo Nordisk's first month discounted cash price of $199 for Wegovy® for new patients. Ro is able to offer this promotion immediately through its seamless integration with Novo Nordisk's direct-to-patient option NovoCare® Pharmacy

Forbes
May 5th, 2025
Charles Barkley On Getting Fit: 'Let'S Get To Work!'

Charles Barkley attends 2024 Steve Harvey Charity Golf Classic at Bear's Best Atlanta on June 05,. More 2024 in Suwanee, Georgia. (Photo by Paras Griffin/Getty Images) Getty ImagesGetting fit has not only been an ongoing struggle for many Americans, but it’s almost part of the American way of life. Recently, with the emergence of more advanced weight loss remedies, there are more options and perhaps more hope for adults who have long battled obesity during their adulthood.And it might seem that everyone is talking about GLP-1. This relatively new medication can help manage Type 2 diabetes and obesity by regulating appetite by slowing down digestion and promoting a feeling of fullness after eating. But for those who don’t really follow science, or what celebrities are doing to keep most fit, all the acronyms and medical terminology can be daunting.Enter Charles Barkley, the NBA Hall of Famer and sports media talking head, who is also known for his voiceover work on many a TV commercial

PYMNTS
Aug 8th, 2024
Fabric Buys Walmart’S Telehealth Business And Stitches Ai Into Digital Healthcare

Telehealth has evolved from a niche service to a central element of healthcare, a shift accelerated by the COVID-19 pandemic. This evolution reflects a broader move toward digital health solutions that fundamentally change patient care. “We’re creating that on-demand experience for patients to get care through a more omnichannel lens,” Aniq Rahman, founder and CEO of Fabric, explained to PYMNTS in an interview. “We want to give great care virtually so people don’t have to leave their homes.”. Fabric’s care enablement system integrates virtual and in-person services through conversational AI and adaptive interviews. This system, designed by clinicians, enhances care quality, accelerates workflows up to tenfold, reduces call center volume by 15%, and improves appointment slot utilization